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Abstract: 
There are over 600 million people worldwide covering Asian and Oceanic countries including India have the habit of chewing 
areca nut as masticator in different forms. Arecoline (C8H13NO2) has been reported as one of the abundant constituents of areca nut.  
A good number of scientific publications have made Arecoline responsible for oral cancer. Based on observation from clinical 
situation in North East India, one of the most betel quid chewing region of the country, we suspected a link between consumption 
of areca nut and Cerebro Vascular Disease like stroke. Therefore, we considered Low Density Lipoprotein (LDL) receptor as target 
and Arecoline as ligand and studied ligand –target interaction using computational tools. Also we considered High Density 
Lipoprotein (HDL) receptor as another target to see if Arecoline has any binding potential with it over and above LDL receptor. 
Docking result indicated that  Arecoline and Cholesterol both, have affinity towards  extracellular domain of Human LDL receptor 
but affinity of Arecoline is much higher (-12.3560.) than that of Cholesterol(-0.1810). Docking of Arecoline and 1, 2-Hexyl-1-
cyclopentanone thiosemicarbazone (thiosemicarbazone) with Bovine HDL receptor showed that Arecoline also has the potential 
(Score, -6.2690Kcal/Mol) to block HDL receptor though its potential is less than that (score, -10.0509 Kcal/Mol) of control 
(thiosemicarbazone). We, therefore, suggest that by inhibiting endocytosis of LDL cholesterol because of blocking LDL receptor 
function and also by preventing LDL cholesterol uptake by liver from blood because of interference with HDL receptor, Arecoline 
may contribute to atherosclerosis. The study therefore, indicates a positive correlation between chewing of betel quid and Cerebro 
Vascular Disease.  
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Background: 
There are over 600 million people worldwide covering Asian 
and Oceanic countries, have the habit of chewing areca nut as 
masticator in different forms. Chewing the mixture of areca nut 
and betel leaf is a part of cultural tradition, custom or ritual in 
these countries which dates back thousands of years. Arecoline 
(C8H13NO2) has been reported as one of the abundant 
constituents of areca nut. A good number of scientific 
publications have focussed on Arecoline as a responsible agent 
for oral cancer. Interestingly there are some controversial 
scientific reports available about the role of Arecoline in relation 
to oral cancer.  
 
Reports are available that Arecoline inhibits p53, represses 
DNA repair, and triggers DNA damage response in human 
epithelial cells [1]. It is also reported that Arecoline induced 
disruption of expression and localization of the tight junctional 
protein ZO-1 is dependent on the HER 2 expression in human 
endometrial Ishikawa cells [2]. Adverse effects of Arecoline and 
nicotine on human periodontal ligament fibroblasts in vitro has 
also been reported [3]. In a review article it is suggested that 
Areca nut should be highly suspected as a human carcinogen 
but toxicity studies relating to areca nut containing polyphenols 
and tannins are not conclusive, with both carcinogenic and anti-
carcinogenic effects being reported [4]. The mutagenicity and BIOINFORMATION  open access 
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genotoxicity of areca alkaloids has been detected by many 
short-term assays. However, their genotoxicity to oral 
fibroblasts and keratinocytes, the target cells of betel quid, has 
not been identified. It would thus appear that areca nut toxicity 
is not completely due to its polyphenol, tannin and alkaloid 
content [4]. Decreasing interleukin-6 production and induction 
of apoptosis and cell cycle arrest in human basal cell carcinoma 
cells by Arecoline has been reported [5]. Report regarding 
induction of cell cycle arrest, apoptosis, and cytotoxicity to 
human endothelial cells by Arecoline is also available [6]. 
Contradictory report saying that areca nut extract and 
Arecoline induced the cell cycle arrest but not apoptosis of 
cultured oral KB epithelial cells has also been published [7]  
 
I t  i s  t h u s  s e e n  t h a t  o v e r  t h e  last two decades scientists have 
been paying attention to Arecoline only from the point of view 
of cancer. No significant attention has been focussed on other 
possible adverse effect of Arecoline. Although there are some 
reports on possible correlation between Betel Quid chewing and 
Cardiovascular Disease available [8, 9], sufficient evidence for 
the mechanisms of action of Arecoline specifically enhancing 
Cerebro Vscular Disease (CVD) are still lacking. It is observed 
that in North East India – one of the most betel quid chewing 
areas of the country, prevalence of stroke is increasing at an 
alarming rate though there is no hard statistics available and 
stroke patients die or suffer from different degrees of disability 
because of absence of properly organised stroke services in any 
of the privately or publicly funded hospitals. Based on 
observation from clinical situation, we suspected a link between 
consumption of areca nut and stroke. Therefore, we focused on 
Low Density Lipoprotein (LDL) receptor discovered only in 
1985 as our target. We studied the binding potential of 
Arecoline with LDL receptor using computational tools because 
mechanism of endocytosis of LDL cholesterol is LDL receptor 
dependent process. The hypothesis of the work is that if any 
molecule can bind with active site of LDL receptor with higher 
affinity than that of LDL cholesterol, that molecule will have 
atherogenic activity and atherosclerosis in turn is responsible 
for the majority of Cerebro Vascular Diseases (CVD) including 
stroke. Though,  High Density Lipoprotein (HDL) cholesterol is 
a good cholesterol (athero-protective) as it helps in lowering 
LDL cholesterol, article published in the Jan. 13 issue of the New 
England Journal of Medicine 2011 specifically states that a specific 
receptor is essentially required for the athero-protective 
function of HDL as this receptor mediates uptake of cholesterol 
by liver from HDL.We, therefore, also looked at Arecoline HDL 
receptor bonding in silico  to see if Arecoline has any inhibitory 
role on HDL receptor over and above its action on LDL 
receptor. For this experiment, thiosemicarbazone a 
commercially available known HDL receptor inhibitor was 
considered as control.  
 
Methodology: 
The 3D structure of the extracellular domain of human LDL 
receptor (PDB ID: 1N7D) was obtained from RCSB Protein Data 
Bank (PDB). The structure was downloaded in PDB (Text) 
format. The active site of the receptor was predicted using Q-
Site finder [10]. The amino acids forming the first probable 
active site were recorded. The structure of Arecoline and 
Cholesterol were obtained from NCBI PubChem database in 
SDF format. To study the binding efficacy of Arecoline and 
Cholesterol to the human LDL receptor, docking experiment 
was carried out using BiosolveIT FlexX 1.3.0, [11]. The PDB 
structure of human LDL receptor was loaded in the BioSolveIT 
FlexX interface. The bound "12-Tungstophosphate" was 
considered as cofactors of the protein. Analyzing the Q-Site 
Finder result, CYS 337 was considered as the central active site 
amino acid. Active site was defined as an area of 10Å radius 
surrounding CYS 337. Separate docking experiments were done 
for Arecoline and Cholesterol molecule with human LDL 
receptor, taking the same active site and same docking 
parameters. 
 
As structure of human HDL receptor is not available in PDB 
and sequence for human HDL receptor could not be obtained, 
taking into account the c DNA sequence of bovine HDL 
receptor  [12], and the sequence obtained from Uni-Prot 
database (Accession No. O18824), 3D structure of bovine HDL 
receptor was predicted by homology modelling using 
Bhageerath-H tool [13]. Because BLAST against PDB database 
could not show significant alignment. So, the structure was 
predicted with a hybrid approach of homology modelling as 
well as ab initio prediction. Active site of the predicted bovine 
HDL receptor was determined again using Q-Site finder [10]. 
Arecoline and thiosemicarbazone were docked against the 
predicted structure again using BiosolveIT FlexX 1.3.0 [11]. 
 
 
Figure 1: Docking mode of Different Ligands and Receptors. 
(A) Cholesterol bound to Extracellular domain of Human LDL 
Receptor;  (B) Arecoline bound to Extracellular domain of 
Human LDL Receptor; (C) Arecoline bound to Bovine HDL 
Receptor;  (D) Thiosemicarbazone bound to Bovine HDL 
Receptor (The red dotted line represents H-bonding and Green 
curves represents weak interactions) 
 
Discussion: 
The extracellular domain of human LDL receptor consists of 699 
amino acid residues and 38 β-strands. The structure (PDB ID: 
1N7D) was determined using X-Ray Diffraction technique at 
3.7Å resolution at a pH of 5.3 [14]. Analyzing the PDB file with 
Q-site finder, it was observed the most probable active site 
consists of CYS 337, GLN 338, ASP 339, PRO 340, THR 342, CYS 
343, SER 344, GLN 345, LEU 346, CYS 347 and VAL 348. 
Docking result showed that both Arecoline and Cholesterol 
have affinity towards the extracellular domain of human LDL 
receptor. Cholesterol forms one H-bond with SER 432 and other 
weak interactions with TYR 444, ASP 445, THR 446, VAL 447 
and SER 432. The total docking score for cholesterol-LDL BIOINFORMATION  open access 
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receptor is -0.1810, whereas, Arecoline has much higher affinity 
towards the LDL receptor. It forms four H-bonds with the 
active site amino acids, viz. ASP 451, ARG 487, THR 489 and 
ARG 492 and other weak interactions with ARG 487, ASP 451 
and ARG 492. The total docking score of Arecoline-LDL 
receptor is -12.3560. It was observed that much of the energy 
contribution i.e. -16.3511 KCal/mol in the binding of Arecoline 
and LDL receptor is due to the shape complementarity, 
whereas, in case of Cholesterol, it is -6.7911 KCal/mol (Figure 1 
A & B), Table 1 (see supplementary material). 
 
Docking result of Arecoline and thiosemicarbazone with HDL 
receptor is presented in (Figure 1 C & D) Table 1 (see 
supplementary material) from the table it is clearly observed 
that Arecoline also has the potential (Score, -6.2690Kcal/Mol) to 
block HDL receptor though its potential is less than that (score, 
-10.0509 Kcal/Mol) of control. Thiosemicarbazone forms three 
Hydrogen bonds with the active site amino acids viz. PRO 297 
and TRP 246 and other weak interactions with PRO 297, THR 
298 and TRP 246. Whereas, Arecoline forms two Hydrogen 
bonds with TRP 246 and ARG 300 and other weak interactions 
with THR 298, ARG 300 and PRO 297.  
 
Although initial report on betel quid as cardiovascular risk 
factor exists [8, 9], our work predicted that Arecoline - the major 
secondary metabolite of betel quid enhances atherosclerosis by 
interfering with LDL and HDL receptors. The result of our 
study showed that   Arecoline binds with active site of 
extracellular domain of human endothelial LDL receptor with 
higher binding efficacy than that of Chloesterol molecules. This 
may inhibit initiation of endocytosis by LDL receptor thereby 
enhancing deposition of cholesterol in the wall of blood vessels. 
While looking at HDL receptor-Arecoline bonding it is 
observed that Arecoline has 60% bonding potential with HDL 
receptor in comparison to control. The work thus suggests two 
fold activities of Arecoline as risk factor of CVD. Though betel 
quid chewing habit was correlated with CVD earlier, its exact 
mode of action was not explained and a number of possibilities 
have been suggested as follows: (a) Linked to diabetes mellitus 
and metabolic syndrome which are independent risk factor for 
atherosclerosis  [15, 16]; (b) Related to elevated level of 
triglycerides  [17];  (c)Linked to thrombin like enzyme activity 
and defective fibrinolytic action [18, 19]; (d) Stimulates platelet 
aggregation and thromboxane B2 production [20]; (e) Related to 
acute myocardial infarction [9]. Present observation differs from 
all the explanations mentioned above in the context that it has 
given a deeper insight into receptor mediated possible 
molecular mechanism of action of Arecoline in relation to CVD. 
 
Conclusion: 
We, therefore, suggest  that Arecoline may be responsible for 
initiating and accelerating the process of atherosclerosis in the 
population who regularly consume areca nut by the following 
mechanisms: i) by way of inhibition of endocytosis of LDL 
cholesterol by interfering with LDL receptor ii) by preventing 
the uptake of LDL cholesterol by liver by interfering with HDL 
receptor. This study therefore, hints that there is a positive 
correlation between chewing betel quid and stroke or other 
CVD. However, wet lab study either in vitro or in vivo with 
Arecoline is needed to see the activity in real experimental 
situation. This suggestion (if confirmed) will have high 
relevance to the developing nations in the habit of chewing 
betel nut as the incidence of stroke is rising in these population 
and there is very little organised health care frame work to cope 
with this rising tide. Prevention is more cost effective than 
treating the disease. 
 
Acknowledgements: 
MDC, PC & ADT sincerely acknowledge DBT. Govt.of India for 
establishment of Bioinformatics Centre in Assam University, 
Silchar. India. 
 
References: 
[1]  Tsai YS et al. Toxicology. 2008 249: 230 [PMID: 18585839] 
[2]  Giri S et al. BMC Cell Biology. 2010 11: 53 [PMID:20604955] 
[3]  Chang YC et al.  J Clin Periodontol.  2001  28: 277 [PMID: 
11284543] 
[4]  Jeng JH  et al. Oral Oncol. 2001 37 :477 [PMID:11435174] 
[5]  Huang LW et al.  Toxicol Appl Pharmacol. 2011 258: 199 
[PMID: 22108589] 
[6]  Tseng SK et al. Clin Oral Investig. 2011 [PMID: 21847594] 
[7]  Chang MC et al.  Carcinogenesis. 2001 22: 1527 [PMID: 
11532876] 
[8]  Chu NS, J Formos Med Assoc. 1993 92: 835 [PMID: 7904868] 
[9]  Hung DZ & Deng JF, Vet Hum Toxicol. 1998 40: 25 [PMID: 
9467205] 
[10]  Laurie AT & Jackson RM, Bioinformatics. 2005 21: 1908 
[PMID: 15701681] 
[11]  Stahl M, Perspectives in Drug Discovery and Design. 2000 20: 
83 
[12]  Rajapaksha WRAKJS et al.  Molecular and Cellular 
Endocrinology. 1997 134: 59 [PMID: 9406850] 
[13]  Dhingra P et al. InCOB. 2011  
[14]  Rudenko G et al. Science. 2002 298: 2353 [PMID: 12459547] 
[15]  Yen AM et al.  Am J Clin Nutr. 2006 83: 1153 
[PMID:16685060] 
[16]  Mannan N et al. Br J Nutr. 2000 83 :267 [PMID:10884715] 
[17]  Geluk CA et al. Metabolism. 2004 53: 49 [PMID: 14681841] 
[18]  Phatak AG, Indian Journal of Orolaryngology. 1979 31: 103  
[19]  Phatak AG, Am J Clin  Pathol. 1984 81: 623 [PMID: 6720629] 
[20]  Jeng JH et al.  Free Radical Biol Med. 2002 32: 860 
[PMID:11978487] 
 
 
Edited by P Kangueane 
Citation: Choudhury et al. Bioinformation 8(5): 229-232 (2012) 
License statement: This is an open-access article, which permits unrestricted use, distribution, and reproduction in any medium, 
for non-commercial purposes, provided the original author and source are credited. 
 
 
 
 BIOINFORMATION  open access 
 
ISSN 0973-2063 (online) 0973-8894 (print)     
Bioinformation 8(5): 229-232 (2012)  232   © 2012 Biomedical Informatics
 
Supplementary material: 
 
Table 1: Hydrogen bond forming components of HDL receptor and LDL receptor with Arecoline, Cholesterol and 
thiosemicarbazone 
H-Bond forming atoms  Bond length (Å)  Bond Energy  
(KCal/Mol) 
Total Docking Score 
(KCal/Mol) 
Ligand Receptor       
1, 2-Hexyl-1-cyclopentanone thiosemicarbazone  HDL Receptor      -10.0509 
H37 O-PRO  297  1.93  -3.84   
H38 O-PRO  297  2.09  -3.72   
N12 HE1-TRP  246  1.60  -3.86   
Arecoline HDL  Receptor       
O2 HE1-TRP  346  1.95  -3.70  -6.2690 
O1 HH11-ARG  300  1.91  -4.70   
Arecoline LDL  Receptor       
O6 HH21-ARG  492A  1.69  -3.62   
O8 HG1-THR  489A  1.67  -4.19  -12.3560 
H25 OD1-ASP  451A  1.82  -8.30   
O8 HH21-ARG  487A  1.89  -0.24   
Cholesterol LDL  Receptor       
O1 HG-SER  432  A  1.96  -4.70  -0.1810 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 